Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc.

Biotechnology • Healthcare • Waltham, MA, United States • XLO (NCM)

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

857 524 2466 828 Winter Street, Waltham, MA 02451, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Xilio Therapeutics Extends Cash Runway Into 2027 - TipRanks
TipRanks • Jan 5
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results - Yahoo Finance
Yahoo Finance • Nov 13
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - GlobeNewswire
GlobeNewswire • Aug 14
Xilio Therapeutics (NASDAQ: XLO) posts 40% ORR in MSS mCRC with high plasma TMB in Phase 2 - Stock Titan
Stock Titan • Nov 7
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - PR Newswire
PR Newswire • Feb 12

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Xilio Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Xilio Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Xilio Therapeutics, Inc. have?
Xilio Therapeutics, Inc. has approximately 64 employees.
What industry is Xilio Therapeutics, Inc. in?
Xilio Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Xilio Therapeutics, Inc. a publicly traded company?
Yes, Xilio Therapeutics, Inc. is publicly traded under the ticker symbol XLO on the NCM. The company has a market capitalization of approximately $0.03 billion.
Where is Xilio Therapeutics, Inc. headquartered?
Xilio Therapeutics, Inc. is headquartered in Waltham, MA, United States at 828 Winter Street, Waltham, MA 02451, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.